Objective: To analyze the effectiveness and tolerability of perampanel across different seizure types in routine clinical care of patients with idiopathic generalized epilepsy (IGE). Methods: This multicenter, retrospective, 1-year observational study collected data from patient records at 21 specialist epilepsy units in Spain. All patients who
| INTRODUCTION
Idiopathic generalized epilepsies (IGEs) are an important and common group of epilepsy syndromes, accounting for up to 30% of epilepsy cases in children and adolescents. 1 Seizures in these syndromes are often considered easy to treat, and the long-term prognosis is good for many people -for example, generalized tonic-clonic seizures (GTCS) on awakening. 2 Remission is less likely in other syndromes, such as juvenile myoclonic epilepsy (JME), where up to 40% of people do not achieve long-lasting seizure freedom. 3 There are few randomized controlled trials of antiepileptic drugs (AEDs) in these patient populations, particularly for those with refractory seizures, and obstacles to trials include the often low frequency of GTCS, the complexity of syndrome diagnosis and classification, and difficulty counting some seizure types (such as frequent myoclonic or absence seizures). In addition, the refractory population from which trial subjects can be recruited is reasonably
Key Points
• One hundred forty-nine people with IGE were treated with perampanel, and 83% remained on treatment after 1 year • Perampanel improved seizures in most patients, and was effective regardless of epilepsy syndrome (juvenile myoclonic epilepsy, GTCS only, and absence epilepsies) • All seizure types responded to perampanel: at 1 year, 62.6% were free of GTCS, 64.6% were free of myoclonic, and 51% of absence seizures • Few patients had worsening of any seizure type with perampanel treatment • The most common adverse events were irritability, somnolence, and dizziness small, as current treatments are effective in many patients. 4, 5 Few AEDs are approved specifically for IGE, and the European Medical Association recently recommended that valproic acid-one of the most widely used drugs in IGE-should not be used in female patients once they reach childbearing age unless the conditions of the new pregnancy prevention program are met. 6 This highlights the limited drug options available and the need for new options supported with good data across all seizure types in IGE.
Perampanel is a noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) receptor antagonist that has shown broad-spectrum anticonvulsant activity in preclinical models. 7 Positive randomized controlled trials and open-label extension studies in patients with refractory focal seizures [8] [9] [10] [11] [12] [13] and primary GTCS in IGE have been undertaken. 14 Once-daily perampanel (4-12 mg) is approved in Europe and the United States as adjunctive therapy (and monotherapy in the United States) for partial-onset seizures (POS) in patients aged ≥12 years, and for primary GTCS in IGE.
Evidence of drug effectiveness and tolerability in the "usual circumstances of health care practice" is recognized as a valuable addition to data from clinical trials. 15 Such real-world evidence is particularly important in conditions like IGE because many patients have complex disorders and comorbidities and are typically excluded or not wellrepresented in clinical trials, and because optimal dosing and titration will differ from the rigid schedules required in clinical trials. 16, 17 Published real-world data with perampanel is mainly from patients with focal seizures, [18] [19] [20] [21] [22] [23] [24] [25] or small case series in specific seizure types, like progressive myoclonic epilepsies or drug-resistant myoclonic seizures. [26] [27] [28] [29] [30] The phase III perampanel trial in IGE included few patients with myoclonic or absence seizures, so the effect of perampanel on these seizure types could not be determined. 14 The aim of our study was to collect data to analyze the tolerability and effectiveness of perampanel across different seizure types in a large population with IGE, and to evaluate prognostic factors related to outcomes.
| MATERIALS AND METHODS

| Study design
The GENERAL (idiopathic GENERALized epilepsy treated with perampanel) study was a multicenter, retrospective, 1-year observational study involving epilepsy specialists from 21 Spanish hospitals, and was conducted to assess the safety and effectiveness of perampanel in IGE in a real-world setting. The study protocol was approved by the ethics committee at the University Hospital and Polytechnic La Fe and followed the Declaration of Helsinki code of ethics. Participating hospitals and physicians are listed in full in Table S1 . All patients who were diagnosed with an IGE syndrome and who were initiated on perampanel before December 2016, were screened retrospectively for inclusion in the study. Inclusion criteria were written informed consent by the patient or legal representative; age ≥12 years; diagnosis of an IGE syndrome; prior history of GTCS; treatment with perampanel according to usual clinical practice at the center; and perampanel start date ≥1 year before closing the database (December 2017). Exclusion criteria were unreliable clinical records and unclear electroclinical diagnosis of IGE. Centers were included in the study if their clinical practice matched the study methodology to allow extraction of appropriate information from clinical charts. The study followed the principles of Good Clinical Practice and was approved by the ethics committee of the Hospital La Fe.
| Data collection
Data were collected from patients' clinical records and kept according to usual clinical practice at each center by participating physicians. Patients were seen routinely at baseline, 3, 6, and 12 months (minimum: baseline and 12-month visit).
Diagnosis and classification of IGE followed the principles of the 2017 International League Against Epilepsy (ILAE) classification of the epilepsies. 31 Diagnosis of generalized epilepsy was made on clinical grounds, supported by the finding of typical interictal EEG discharges (ie, generalized spike-wave). In patients who had GTCS but normal electroencephalography (EEG) findings, supportive evidence (eg, myoclonic jerks, relevant family history) was required. All diagnoses were checked by a physician at the coordinating center, queries were requested (including EEG data) before inclusion in the study, and patients who did not meet criteria for IGE diagnosis were excluded. IGE syndrome was recorded as follows: childhood absence epilepsy (CAE); juvenile absence epilepsy (JAE); juvenile myoclonic epilepsy (JME); GTCS only (formerly GTCS on awakening). 31, 32 Some patients met criteria for IGE but had other syndrome diagnoses (Jeavons syndrome [eyelid myoclonic with absences] and adult-onset absence epilepsy). 33 Data were extracted from patient charts and seizure diaries at baseline and each visit (Data S1). Baseline seizure frequency was calculated over the 3 months prior to initiation of perampanel or, if no seizures, during the prior 12 months. GTCS frequency was calculated as mean seizures per month. For myoclonic and absence seizures (which are often frequent and uncountable), mean number of days with seizures per month was calculated. Physicians also provided a subjective evaluation of myoclonic and absence seizures (worsened, no change, improved), based on the perception of seizure frequency, intensity, and/or duration relative to baseline.
Physicians asked patients and/or caregivers/relatives about adverse effects (AEs) at each visit, and AEs that physicians considered related to perampanel were included in this analysis. All patients had at least one blood test (complete blood count and biochemistry), and vital signs were recorded when considered relevant by physicians.
| Study variables
The effectiveness population comprised all patients who fulfilled the inclusion criteria and had at least one effectiveness measurement. Last observation carried forward (LOCF) was used to handle missing data. The safety population comprised all patients who fulfilled the inclusion/exclusion criteria and received at least one dose of perampanel.
The primary end points were the proportion of patients free of GTCS at 12 months and the proportion free of all seizures types at 12 months. Seizure freedom was defined as no seizures since the prior visit, which for the 12-month visit meant no seizures during at least the prior 6 months, and for the 3-and 6-month visits meant no seizures since baseline or 3-month visit, respectively.
Secondary end points included the following: change in seizure frequency (or days with seizures) at 12 months relative to baseline for each seizure type; the proportion of responders at 12 months for GTCS (patients with ≥50% reduction in GTCS frequency at 12 months relative to baseline); and retention rate on perampanel at 12 months.
Safety end points included the proportion of patients with AEs at 3, 6, and 12 months, AE severity (mild, moderate, severe), and the proportion with AEs that led to discontinuation at 3, 6, and 12 months.
Exploratory analyses examined outcomes in the following patient subgroups: by epilepsy syndrome; in those previously or currently taking valproic acid and those never taking valproic acid; in patients initiating perampanel as early add-on (0-2 prior AEDs, including current AED[s]) and late add-on (≥3 prior AEDs); patients initiating perampanel due to poor efficacy and due to poor tolerability of prior AEDs; and patients maintained on perampanel monotherapy.
| Statistical analysis
Continuous variables were summarized by descriptive statistics and categorical variables by absolute frequencies and percentages.
In the effectiveness analyses, changes over time in seizure-free rates for each seizure type were analyzed using the Cochran test and the McNemar test. Variations in the frequency of seizures and days without seizures were analyzed using the Friedman test and the Wilcoxon test. Subgroup analyses used the chi-square test (or Fisher's exact test) for comparing categorical variables and the MannWhitney U test for continuous variables.
In the tolerability analyses, AEs and their intensity were described using absolute frequencies and percentages. Subgroup analyses used the chi-square test (or Fisher's exact test).
All statistical analyses were performed using SPSS version 19 (IBM Corporation, Armonk, New York). The threshold of significance was P < 0.05.
| RESULTS
| Patient characteristics, disposition, and retention rate
Of 159 patients in the database, 149 (93.7%) fulfilled the inclusion/exclusion criteria and received at least one dose of perampanel. The main reason for exclusion was lack of confirmation of IGE diagnosis. The effectiveness and safety populations both comprised 149 patients. At baseline, GTCS were most common, with myoclonic and absence seizures occurring at lower frequency ( Table 1) .
The most frequently used prior AEDs were levetiracetam in 112 patients (75.2%), valproic acid in 106 (71.1%), lamotrigine in 63 (42.3%), zonisamide in 57 (38.3%), and topiramate in 34 (22.8%). The decision to start perampanel was made because of lack of effectiveness with prior AEDs in 81.9% of patients (122/149); poor tolerability with prior AEDs in 17 (11.4%); poor compliance in 1 (0.7%); poor compliance and lack of effectiveness in 2 (1.3%); poor tolerability and poor compliance in 2 (1.3%); and other reasons in 4 patients (2.7%).
The retention rate at 12 months was 83.2% (Table 2) . Of the 25 patients who discontinued perampanel, 16 did so because of AEs, 6 because of lack of effectiveness, and 3 because of both.
| Patterns of AED use
| Perampanel titration and exposure
The median perampanel dose at 12 months was 6 mg (Table 2); 4 mg was the most common dose (48% of 124 patients), and 95% were taking 4, 6, or 8 mg (Table S2) perampanel exposure was 12.1 months (range 0.5-13.8 months).
| Concomitant AEDs
The median number of concomitant AEDs at baseline was 2 (range 0-4; mean 1.7), most commonly levetiracetam (79/ 149 patients, 53.0%), valproic acid (52, 34.9%), lamotrigine (35, 23 .5%), and zonisamide (34, 22.8%). Exposure to concomitant AEDs significantly reduced over time from a mean (standard deviation, SD) of 1.7 (0.9) at baseline to 1.5 (0.9) at 12 months (P < 0.001; Friedman test). A new AED was added in 13 patients (8.7%) and at least one AED was discontinued in 50 patients (33%) during followup. The most commonly discontinued AEDs were levetiracetam (18 patients), valproic acid (11), and zonisamide (7) . The change in distribution of the number of concomitant AEDs over time is shown in Figure S1 .
| Effectiveness
| Seizure freedom
At 12 months, 88/149 patients (59.1%) were free of all seizures for at least the previous 6 months, 72/115 (62.6%) were free of GTCS, 31/48 (64.6%) were free of myoclonic, and 24/47 (51.1%) were free of absence seizures (Table 2) . When the whole observation period was considered (mean 12.1 months; range 0.5-13.8), 33.6% of patients (50/149) were free of all seizures; 38.3% (44/115) were free of GTCS; 35.4% (17/48) were free of myoclonic seizures; and 29.8% (14/47) were free of absence seizures.
The proportion of patients who had GTCS, myoclonic seizures, and absence seizures each reduced significantly from baseline to 12 months (P < 0.001 for each seizure type, McNemar test).
| Seizure frequency change and response
The frequency of GTCS was significantly reduced from baseline to 12 months (P < 0.001, Wilcoxon test)-an average 77.8% relative reduction in seizure frequency. Seventy-six percent of patients were responders, most being seizure-free (Table 2, Figure 1 ).
The number of days with myoclonic seizures and with absence seizures was significantly reduced from baseline to 12 months in patients with these seizures at baseline ( 
| Safety and tolerability
By 12 months, 49.7% of patients (74/149) had experienced at least one AE; these were mild or moderate in the majority (67/74). Most AEs occurred within the first 3-6 months, with few additional AEs over the remaining follow-up (Table 3 ). The most common individual AEs were irritability, somnolence, and dizziness, and overall 12.8% of patients discontinued due to AEs. Weight gain was reported in 5 patients over 12 months (n = 4 mild; n = 1 moderate), and no patients discontinued as a result. At 12 months, there was no statistically significant difference in perampanel dose between patients with AEs (median 5.6 mg) and without AEs (5.3 mg; P = 0.457, Mann-Whitney U); in overall AE rates based on concomitant AEDs; or in AE rates at 3 months in those patients with slow titration (51.0%) and fast titration (37.2%; P = 0.113, chisquare test). Psychiatric AEs were reported in 41 patients, of whom 13 (8.7%) discontinued (8 due to moderate psychiatric AEs, 5 due to severe psychiatric AEs). Discontinuation was due exclusively to psychiatric AEs in 9 patients (6.0%), with other AEs and lack of efficacy contributing in the other 4 patients. Irritability alone led to discontinuation in 3 patients (2.0%), and overall 11 patients who discontinued had irritability (7.4%). There was no significant difference in perampanel dose between patients with and without psychiatric AEs, between patients with psychiatric AEs who discontinued and those who continued, or in the frequency of psychiatric AEs between patients with psychiatric comorbidity (39.5%) and without (23.4%; P = 0.056, chi-square), although a trend toward higher rates with comorbidity was evident. The rate of psychiatric AEs was statistically higher in patients taking topiramate at the end of follow-up (n = 5) than those not taking topiramate (P = 0.020, Fisher's exact test), and irritability was also more common in patients taking topiramate at the end of followup than not (P = 0.011, Fisher's test); no differences in psychiatric AE rates were found for any other concomitant AED, including levetiracetam.
| Exploratory analyses
Perampanel improved seizure outcomes across all subpopulations tested: those with prior and no prior valproate use; those starting perampanel because of lack of effectiveness on prior AEDs or side effects on prior AEDs; those starting perampanel as early add-on (0-2 prior AEDs) and late addon (≥3 prior AEDs); across different concomitant AED combinations; and across different epilepsy syndromes. Full details are in Data S2, and notable findings are summarized here.
| Patients previously on valproate
Valproate had been used by 106 patients (71.1%, including 52 patients taking valproate at baseline), and use was highest among patients with absence seizures (Section A in Data S2). Patients treated previously with valproate had a significantly longer mean duration of epilepsy and more prior and more concomitant AEDs. Retention rate, time on perampanel, and reductions in the frequency of GTCS, myoclonic seizures, and absence seizures were similar for patients with and without prior valproate treatment. The seizure-free rate at 12 months was significantly lower in patients with prior valproate than without, both overall (54% vs 72%) and for absence seizures (43% vs 80%). Frequency of AEs was higher in patients with prior valproate than without (55.7% vs 34.9%; P = 0.022, chisquare test), but rates of discontinuation were not significantly different (15.1% vs 7.0%; P = 0.278, Fisher exact test).
| Perampanel as early add-on
Perampanel was used as early add-on (after 0-2 prior AEDs) in 53 patients and late add-ons (after ≥3 prior AEDs) in 96 patients. Retention rate at 12 months was significantly higher in those with early (92.5%) than late addon (78.1%; P = 0.038, Fisher's exact test). Significant reductions over time were seen in both groups (early and Categories of percent change in frequency of generalized tonic-clonic seizures (GTCS) relative to baseline, in patients who had GTCS at baseline (N = 115). Worsening seizures was defined as >10% increase in frequency relative to baseline; no change was defined as ±10% change in frequency relative to baseline; improvement <50% was defined as reduction in seizure frequency >10% and <50% relative to baseline late add-on) in the frequency of GTC, myoclonic, and absence seizures. More patients in the early add-on group achieved freedom from all seizures at 12 months (71.7%, 38/53) than in the late add-on group (52.1%, 50/96; P = 0.020, chi-square test). This pattern was also apparent for GTC, myoclonic, and absence seizures, although the differences were not statistically significant. Seizure-free rates of 62% (myoclonic) and 44% (absence) were reached by patients with >2 prior AEDs, who could be considered as having drug-refractory seizures before addition of perampanel (Section D in Data S2).
The proportion of patients experiencing AEs (41.5% vs 54.2%) or discontinuing due to AEs (7.5% vs 15.6%) was not statistically different between early and late add-on.
| Concomitant AEDs
The seizure-free rate at 12 months tended to decline as the number of prior AEDs (including baseline concomitant AEDs) increased (Figure 2A) , and as the number of concomitant AEDs at baseline increased ( Figure 2B) . At 12 months, 94 patients were taking perampanel with just one other AED, allowing examination of "pure" AED combinations ( Figure 2C ).
| Patients on perampanel monotherapy
At 12 months, 7/149 patients (4.7%) had been on perampanel monotherapy for at least 6 months, and 6 of the 7 were seizure-free. The frequency of GTCS was significantly reduced over the observation period (from mean 0.8/ mo at baseline to 0.03/mo at 12 months; P = 0.001, Friedman test, N = 6); relative reduction of 96.3% (Section E in Data S2). Table 4 shows outcomes by epilepsy syndrome: 51 patients had GTCS only; 60 had JME; and 37 had absence epilepsies (21 JAE; 10 CAE; 6 adult-onset absence).
| Epilepsy syndromes
Retention rates at 12 months were similar across the groups (80%-85%). GTCS frequency was significantly reduced relative to baseline in all 3 syndrome groups at 12 months, and there were no differences in seizure freedom rates overall or for GTCS seizures, between the syndrome groups (Table 4) .
| DISCUSSION
The GENERAL study provides the first large-scale realworld data with perampanel in people with IGE. In our cohort, the GTC seizure-free rate (63%) is higher than reported in the placebo-controlled phase III study of adjunctive perampanel in refractory IGE (31%), which recruited people with more refractory and frequent GTCS (mean of 2.6 PGTCS/mo at baseline vs 0.7/mo in our cohort).
14 Few patients in the trial had myoclonic or absence seizures, and the authors could only conclude that there was "no evidence for exacerbation of these seizure subtypes." A post hoc analysis showed freedom from myoclonic seizures in 47% of perampanel patients (vs 13% with placebo) and freedom from absence seizures in 22% (vs 12%). 34 Other reports of perampanel use in people with myoclonic seizures have focused on patients with severe progressive myoclonic epilepsies or highly refractory seizures. In routine perampanel use in 31 patients with drug-resistant myoclonic seizures, 32.3% were free of myoclonic seizures at 6 months and 47.1% were free of GTCS. 28 The lower rates compared with our study could be explained by their drug-resistant population, which included people with progressive The remaining AEs, each occurring in one patient, were the following: memory disturbances, psychosis, anorexia, libido increase, self-aggression, bradyphrenia, diarrhea, gastrointestinal disturbances, constipation, suicidal ideation, emotional lability, blurred vision.
myoclonic epilepsies and other severe conditions. Responder rates were higher in the 12 patients with IGE than in their patients with myoclonic seizures due to anoxia, mitochondrial diseases, and conditions like Lennox-Gastaut syndrome. 28 Positive (often dramatic) responses of myoclonic and GTC seizures to perampanel have been reported in 12 patients with Unverricht-Lundborg disease, 30 atrophy (DRPLA), 29 Lafora disease, 27, 36 and myoclonic status epilepticus. 37 We could not find any published data on perampanel in absence seizures in IGE. In our cohort, fewer people with absence seizures achieved seizure freedom (51%) than for myoclonic (65%) or GTC seizures (63%), although number of days with absence seizures was still significantly reduced relative to baseline and worsening of absences seizures was rare.
It is difficult to compare our results with perampanel with other AEDs, as there have been no comparative studies and there is significant heterogeneity in study populations and outcome measures. An analysis of computerized database and EEG records at large adult and pediatric epilepsy clinics showed that overall 54.3% of 962 patients achieved a 1-year period of remission with AED treatment: this was most likely with valproate monotherapy (52.1%), with lower rates for topiramate (34.6%) and lamotrigine (16.7%). 38 The Standard and New Antiepileptic Drugs (SANAD) study evaluated the effectiveness of valproate, lamotrigine, and topiramate in patients with generalized or unclassified epilepsy. The 1-year remission rates (from all seizures) was 43% for valproate, 32% for lamotrigine, and 39% for topiramate. 39 Our seizure-free rate (33.6%, when the entire observation period was considered), is consistent with the rates with older AEDs in these studies. Although perampanel was effective regardless of the number of prior AEDs, it was more effective in the early add-on setting (72% seizure-free) than after 3 or more AEDs (52% seizure-free). This pattern is seen for AEDs in general-as fewer prior AEDs is a proxy for less refractory epilepsy-and has been shown with perampanel in focal seizures in the phase III trials 40 and in observational studies. 23 In a study of first add-on use in 15 patients with uncontrolled secondarily generalized seizures, 80% of patients were free of these seizures 1 year after addition of perampanel. 41 Perampanel has also been studied as monotherapy-Gil-Nagel et al 42 reported a responder rate of 80% and a seizure-free rate of 45% during the first 3 months of perampanel monotherapy, in an observational study in 60 patients with focal and generalized seizures. In our limited group of 7 patients who achieved monotherapy with perampanel, 6 were free of GTCS at 1 year, none reported AEs, and none discontinued.
Rates of discontinuation due to AEs were lower in our cohort (12.8%) than in other observational studies with perampanel. 19, 21, 23, 43 Our lower rate could be related to use in earlier add-on, and lower discontinuation rates (7%) have been reported with earlier use (first add-on: 1/15; monotherapy: 4/60). 41, 42 Eighty percent of our patients were maintained on 4 or 6 mg perampanel, and at 3 months, just over half of patients were being titrated in 2-mg increments every 2 weeks, and a quarter every 4 weeks. This conservative dosing and titration scheme may contribute to the low discontinuation due to AEs and may also explain why we found no difference in AE rates between slow and fast titration schemes. The numerically higher AE rate in patients on slow titration may be caused by a propensity to use a slower titration scheme in patients who are expected to (or who start to) experience AEs when initiating perampanel. The individual AEs reported in our cohort of patients are consistent with previous studies, with irritability (23%), somnolence (15%), and dizziness (14%) being most common. Psychiatric AEs occurred in 28% and contributed to discontinuation in 8.7% (n = 13), although the majority were not classed as severe and only 9 patients (6.0%) discontinued solely due to psychiatric issues. This discontinuation rate is consistent with those of the phase III trials in IGE (6.2%), 14 and lower than other observational series with more refractory cases (eg, 16.7%). 43 Of interest, cognitive AEs such as memory disturbances were reported by <1% of our patients, supporting previous findings that perampanel has minimal cognitive impact, 44 patients treated with perampanel improved scores in a computerized test of cognitive speed). 45 This is particularly important in a condition like IGE where cognition is relatively well conserved to avoid causing cognitive impairments that could severely impact quality of life. 46 The effect of in utero exposure to AEDs is a very important consideration. No pregnancies were reported in our cohort, and there were too few pregnancies in the perampanel clinical trials (25 pregnancies in >5000 patients across epilepsy and nonepilepsy studies) 47 to determine the specific risks with perampanel. We await data from the North American and European pregnancy registries. Addition of perampanel led to improvements in seizure outcomes, regardless of concomitant AEDs. Even in patients previously treated with (and presumably failed) valproic acid (which is a strong predictor of refractory seizures in IGE), 48 43% were free of absence seizures and 54% were free of all seizures at 1 year. Consistent with previous findings with perampanel when added to levetiracetam, 23 ,49 the specific concomitant AEDs did not tend to affect the incidence of AEs. The exception was the possibly anomalous increased psychiatric AEs with perampanel plus topiramate, based on only 5 patients. Limitations of the GENERAL study are its retrospective design (which carries the risk of missing relevant information from patient clinical charts), lack of randomization, lack of control group, and the effect of perampanel on EEG was not analyzed. In addition, patients categorized with adult-onset absence epilepsy may have had undiagnosed childhood/juvenile-onset absences. The strengths include the ability to include patients who are routinely treated with AEDs but are excluded from randomized controlled trials. There are fewer clinical trials in IGE than for focal epilepsies, so there is a great need for real-world data in these populations.
In conclusion, in our patients with IGE and multiple seizure types, the addition of perampanel was associated with reductions in the frequency of GTC, myoclonic, and absence seizures, regardless of concomitant AEDs, and epilepsy syndrome. Seizure worsening was rare, and perampanel was well tolerated. Further studies, particularly in patients with myoclonic and absence seizures, are needed to consolidate these results.
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